Rises to its highest levels since December on above 9x average volume, posting gains alongside its peer in the cancer treatments development space, Syndax Pharmaceuticals (SNDX); co's pipeline includes a menin-MLL inhibitor, KO-539.
- Sector: Healthcare
- Industry: Biotechnology
- Full Time Employees: 57
- Founded in 2014
- HQ inSan Diego, California
- http://www.kuraoncology.com
No comments:
Post a Comment